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Case Presentation
Case 1
A 32-year-old male commercial fisherman
worked on the Pocomoke River, a tributary
of the Chesapeake Bay on the Eastern Shore
of Maryland, since age 16 without any sig-
niﬁcant illness until October 1996. In asso-
ciation with harvesting multiple species of
fish with deep, penetrating ulcers, the
patient had initial onset of memory impair-
ment, headache, hypersensitivity to bright
light, fatigue, cough, muscle ache, skin rash,
diarrhea, and anorexia. Subsequently, the
patient was treated by several local physicians
with antibiotics for recurrent pneumonia
(seven episodes in 6 months). The diagnoses
of pneumonia were based on clinical parame-
ters alone, without additional confirmatory
tests. The patient lost 40 pounds, became
weak and lethargic, and continued to suffer
from the symptoms listed above. He contin-
ued to work in the estuaries. 
The patient was exposed to an active ﬁsh
kill 5–8 August 1997 (Table 1), which was
thought to be caused by the estuarine
dinoflagellate, Pfiesteria piscicida, or other
members of the toxic Pfiesteria complex
(TPC), after which he experienced increased
severity of the symptoms. The patient was
evaluated by a multidisciplinary team of
researchers from the University of Maryland
and Johns Hopkins University on 19 August
1997 as a participant in a study on human
contact with estuaries around the time of ﬁsh
kills associated with TPC. Neurocognitive
tests indicated an extremely low level of exec-
utive functioning. 
The patient remained ill; he sought med-
ical assistance and was evaluated by an author
(R.C.S.) in September 1997. He reported
that his symptoms (Table 2), which were
unremitting since initial onset, had been exac-
erbated by the August 1997 ﬁsh-kill contact.
Complete blood count, comprehensive meta-
bolic profile, and pulmonary-function test
results were within normal parameters. His
medical history revealed no previous illness
involving neurologic dysfunction, alcoholism,
chronic soft-tissue injury, Lyme disease,
chronic ciguatera-seafood poisoning, or possi-
ble building-related illness. Occupational his-
tory indicated little or no exposure to solvents
or petroleum products, metals fumes,
pesticides, or other neurotoxicants. It was
concluded that his chronic (i.e., symptom
duration > 1 month) illness may have been
caused by estuarine-associated neurotoxins.
The patient was treated with cholestyramine
(CSM), a polymer previously approved by
the U.S. Food and Drug Administration
(FDA) for treatment of hypercholesterolemia
and considered an exempt usage for toxin
elimination, according to a standard protocol
(Table 3). His symptoms improved begin-
ning 36 hr after treatment initiation. He con-
tinued treatment, with subsidence of all
symptoms within 2 weeks and subsequent
regain of weight. His neurocognitive scores
were within normal range when subsequently
evaluated in a 3-month follow-up by the
University of Maryland and Johns Hopkins
University research team.
The patient began a maintenance pro-
gram of two doses of CSM daily while con-
tinuing to work in areas of previous ﬁsh kills.
He stayed well until June 1998, 5 days after
cessation of the CSM prevention regime,
when he again harvested lesioned fish from
the Pocomoke River (Table 1). The patient
presented with a characteristic rash, mild
secretory diarrhea (i.e., non-osmotic, contin-
uation without food or liquid intake), and
exertional cough, and he reported extreme
fatigue (Table 2). Again, the clinical and lab-
oratory tests produced negative results, and
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The human illness designated as possible estuarine-associated syndrome (PEAS) by the Centers
for Disease Control and Prevention (CDC) has been associated with exposure to estuaries inhab-
ited by toxin-forming dinoﬂagellates, including members of the ﬁsh-killing toxic Pﬁesteria com-
plex (TPC), Pﬁesteria piscicida and Pﬁesteria shumwayae. Humans may be exposed through direct
contact with estuarine water or by inhalation of aerosolized or volatilized toxin(s). The ﬁve cases
reported here demonstrate the full spectrum of symptoms experienced during acute and chronic
stages of this suspected neurotoxin-mediated illness. The nonspeciﬁc symptoms most commonly
reported are cough, secretory diarrhea, headache, fatigue, memory impairment, rash, difﬁculty in
concentrating, light sensitivity, burning skin upon water contact, muscle ache, and abdominal
pain. Less frequently encountered symptoms are upper airway obstruction, shortness of breath,
confusion, red or tearing eyes, weakness, and vertigo. Some patients experience as few as four of
these symptoms. The discovery that an indicator of visual pattern-detection ability, visual contrast
sensitivity (VCS), is sharply reduced in affected individuals has provided an objective indicator
that is useful in diagnosing and monitoring PEAS. VCS deficits are present in both acute and
chronic PEAS, and VCS recovers during cholestyramine treatment coincident with symptom
abatement. Although PEAS cannot yet be deﬁnitively associated with TPC exposure, resolution
with cholestyramine treatment suggests a neurotoxin-mediated illness. Key words: cholestyramine,
chronic neurotoxic illness, harmful algal blooms, Pﬁesteria, possible estuary-associated syndrome,
visual contrast sensitivity. Environ Health Perspect 109:539–545 (2001). [Online 14 May 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p539-545shoemaker/abstract.html
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or neurotoxic exposures. CSM treatment
was reinstituted, and his acute illness
resolved within 1 week.
Case 2
A 41-year-old male soil scientist sampled
submerged sediments and porewater for
dinoﬂagellate DNA and pollutants on 19–20
July 1999 in the Chesapeake Bay, Pocomoke
River, and Bulbeggar Creek in Virginia,
where a 4-day fish kill attributed to TPC
activity began on 24 July 1999, and in sur-
rounding areas (Table 1). Sampling involved
direct immersion in water, exposure to spray,
and inhalation of air at the water surface.
Visual acuity and visual contrast sensitivity
(VCS) were measured with the Functional
Acuity Contrast Test (F.A.C.T.) apparatus
(Stereo Optical Co., Inc., Chicago, IL;
Figure 1) (6,7). The test measures the least
amount (threshold) of luminance difference
between adjacent areas (contrast) necessary
for an observer to detect a visual pattern.
VCS is the inverse of contrast threshold.
Visual acuity and VCS measurements before
estuary exposure on 19 July 1999 and at the
end of exposure on 20 July 1999 (Figure 2)
were within normal limits (acuity, Snellen
distance equivalent scores ≤ 20:40; VCS
scores > 64 at 6 cycles/degree of visual arc).
The patient became ill on the night of 21 July
1999, 24 hr after sampling ended. The
patient was seen on 23 July 1999 while suffer-
ing memory impairment, mild confusion,
severe bifrontal throbbing headache, intermit-
tent cramping, profuse secretory diarrhea,
nonproductive cough, fatigue, and abdominal
pain (Table 2). He was previously healthy and
had no history of illness involving neurologic
dysfunction, allergy, asthma, eosinophilia, or
neurotoxicant exposure, and the clinical and
laboratory tests were negative as with Case 1.
VCS was markedly depressed (Figure 2), but
visual acuity was unaffected. The patient met
the case deﬁnition for possible estuary-associ-
ated syndrome (PEAS), a syndrome
described by the Centers for Disease Control
and Prevention (CDC) following human ill-
ness associated with estuarine contact around
the time of the August 1997 TPC-related ﬁsh
kill in Maryland estuaries. Treatment with
CSM was initiated immediately (Table 3).
Symptoms and VCS abnormalities
responded promptly (Figure 2), clearing
completely by 31 July 1999, the ninth day of
treatment.
Case 2 developed a similar acute illness
on 20 October 1999 following estuarine
sampling in areas of the inland Delaware
bays found to contain Pﬁesteria shumwayae,
another member of the TPC (Table 1), when
sampling resumed in May 2000. He treated
himself with CSM at standard doses, with
complete recovery and normal VCS on 25
October 1999 (Figure 2). The patient’s VCS
remained normal on 27 November 1999,
after he stopped taking CSM (Figure 2). He
returned to the inland Delaware bays the
next day (Table 1) and was seen in the clinic
on 1 December 1999 while suffering a third
acquisition of acute illness characterized by
headache, upper airway obstruction, cough,
diarrhea, fatigue, muscle ache, and depressed
VCS (Table 2, Figure 2). Multiple medica-
tions were prescribed, including CSM.
Follow-up was not obtained, but according
to his wife, he took CSM until his symptoms
abated in a few days. She reported that he
had reexposure to the Delaware Bay sam-
pling site on 15 December 1999 and saw a
different physician on 21 December 1999
while experiencing fever, shortness of breath,
and cough. Antibiotics were prescribed and
bronchodilators initiated, followed by
prompt improvement in cough and reduc-
tion of fever. The patient exhibited intense
snoring during the night of 22–23 December
1999, suggestive of upper airway obstruction,
and was found dead in the morning.
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Table 1. Estuarine exposure and illness.
PEAS  Illness  Estuarine contact < 2 weeks Dead or lesioned Ever tested 
condition date before illness onset ﬁsh contact positive for TPC References
Case 1 Chronica Oct 1996–Sep 1997 Pocomoke River, MD Y Y (1)
Acute Jun 1998 Pocomoke River, MD Y Y (1)
Case 2 Acute Jul 1999 Pocomoke River, MD  Y Y (1,2)
and Bulbeggar Creek, VA
Acute Oct 1999 Indian River, DE N Y (3)
Acute Dec 1999 Rehoboth Bay and tributaries, DE Y Y (3)
Case 3 Acute Dec 1998 Chicamacomico River, MD Y Y (4)
Acute Feb 1999 Chicamacomico River, MD Y Y (4)
Cases 4 and 5 Chronic Sep 1998–Mar 1999 Back Creek, Manokin River, MD Y Y (4,5)
Acute Jul 1999 Back Creek, Manokin River, MD N Y (4,5)
aChronic PEAS is deﬁned as PEAS symptoms present > 1 month.
Table 2. Symptoms reported.
CDC
Case/ Skin Burning Eye Upper Muscle Light Short of Muscle Abdominal
type (date) Memorya Confusiona Headache rasha skina irritation respiratory cramp GI Concentration sensitive Cough breath Fatigue ache Weakness pain Vertigo
Case 1
Chronic + + + + + + + + + +
(Oct 1996–Sep 1997)
Acute (5 Jun 1998) + + + +
Case 2
Acute (Jul 1999)b ++ + + + + +
Acute (Oct 1999)b ++ + + + +
Acute (Dec 1999)b ++ + + + + +
Case 3
Acute (Dec 1998) + + + + + +
Acute (Feb 1999)b ++ + + + + + + +
Case 4
Chronic + + + + + + + + + + +
(Sep 1998– Mar 1999)
Acute (Jul 1999) + + + + + + + + + + +
Case 5
Chronic + + + + + + + + + +
(Sep 1998–Mar 1999)
Acute (Jul 1999) + + + + + + + + + +
GI, gastrointestinal.
aThe CDC case deﬁnition for PEAS includes memory loss, confusion, skin rash and burning skin sensation af any duration. Other symptoms must persist for > 2 weeks. bCSM treatment was initiated and all symptoms
resolved in less than 2 weeks from onset.Findings at autopsy included multiple foci of
patchy bronchopneumonia, hyalinized air-
ways consistent with reactive airway disease,
and an intense eosinophilic inﬁltrate of soft
tissues above the larynx.
Case 3
A 75-year-old male recreational fisherman
began to notice bass and perch with punched
out ulcerative lesions during November 1998
in the Chicamacomico River, Maryland, a
tributary of the Chesapeake Bay located 50
miles from the Pocomoke River. The patient
remained well until 16 December 1998 when
he caught several fish with lesions from the
Chicamacomico (Table 1). He reported that
the water felt “hot” to the touch, even
though the water temperature was 46°F. The
patient reported abrupt onset of tearing dur-
ing exposure, and subsequent eye irritation,
headache, confusion, diarrhea, cough, and
vertigo when seen in the clinic on 18
December 1998 (Table 2). His VCS was
markedly reduced (Figure 3), although visual
acuity was normal. He was previously healthy
and had no history of neurotoxicant exposure
or illness involving neurologic dysfunction,
and the complete blood count, comprehen-
sive metabolic proﬁle, and pulmonary-func-
tion test results were negative. He enrolled in
an ongoing double-blinded, placebo-con-
trolled, crossover trial designed to assess the
efficacy of CSM treatment for PEAS. Two
weeks of treatment with placebo gave no
improvement in VCS (Figure 3) or symp-
toms. VCS, but not visual acuity, improved
markedly with CSM treatment (Figure 3)
coincident with symptom abatement. The
time course of VCS recovery is shown for the
middle spatial frequency in Figure 3. 
The patient was well until he returned to
the same area of the Chicamacomico on 16
February 1999 (Table 1). Again, the water
temperature was cold, 42°F, and he caught
lesioned ﬁsh (Figure 4). Two days later, his
clinical presentation suggested a more severe
case of PEAS. The syndrome consisted of a
rash similar to that seen in previous PEAS
cases, memory impairment, confusion,
headache, diarrhea, hypersensitivity to bright
light, cough, and fatigue (Table 2). VCS was
markedly reduced, similar to that seen dur-
ing his first bout of PEAS. He was again
treated with CSM, which he took for 8 days.
His symptoms abated and VCS, shown at
the midspatial frequency in Figure 3,
returned to normal during treatment. He
has remained well while avoiding known
endemic TPC areas.
Cases 4 and 5
A 28-year-old female and her 37-year-old
husband became ill in the fall of 1998 after
catching crabs in a tributary of the Manokin
River (in Maryland 20 miles north of
Pocomoke City) known to be inhabited by
TPC (Table 1). Both reported a burning
skin sensation when touching the water, and
within 24 hr they experienced abrupt onset
of memory impairment, headache, skin rash,
red stinging eyes, difﬁculty in concentrating,
light sensitivity, cough, fatigue, and abdomi-
nal pain. Only the male reported diarrhea
(Table 2). Their symptoms persisted, but
they did not seek medical assistance for
almost 6 months. 
The husband came to the clinic on 6
March 1999 and described his symptoms
and the events surrounding onset. He scored
positive on the VCS test; was negative on
the blood, metabolic, and pulmonary func-
tion tests; and had no history of confound-
ing illness or neurotoxicant exposure. He
was diagnosed with chronic PEAS and vol-
unteered for the clinical trial on CSM effi-
cacy. On 10 March 1999, the woman
accompanied her husband to his initial fol-
low-up visit and requested medical assis-
tance. She also showed severely reduced
VCS (Figure 5) and described similar symp-
toms (Table 2) and the same events prior to
onset as her husband (Table 1). Clinical and
laboratory tests were negative, and she was
free of potentially confounding factors other
than a history of head trauma. She attributed
mild memory impairment to the head
trauma, but reported exacerbation since
symptom onset. She was diagnosed with
chronic PEAS and volunteered for the CSM
clinical trial. She showed no improvement
when she was retested on 12 March 1999
while taking the randomly assigned placebo
medication. At the follow-up visits on 20
March 1999, the husband reported complete
resolution of symptoms and showed normal
VCS, whereas the wife stated that she had
stopped taking her medication (the placebo)
on 17 March 1999 and began taking her
husband’s medication (CSM). She was
adamant that she receive the same medica-
tion that her husband was taking because his
symptoms were dramatically reduced while
hers persisted. She was treated with CSM,
and her symptoms, including a rash on her
breast that had not responded to self treat-
ment in 6 months, abated within 10 days
and VCS returned to the normal range
(Figure 5). Visual acuity was unchanged.
Both patients returned to a nearby area
of the Manokin River System for recreation
on 25 July 1999. More than 1 hr after being
near the water, both made initial water con-
tact and again felt a burning skin sensation,
which prompted them to leave the area. Fish
kills were reported in this part of the
Manokin on 10 August 1999, and the pres-
ence of TPC was conﬁrmed (Table 1). Both
patients experienced symptom onset within
36 hr, but waited 2 weeks before seeking
medical assistance. The woman presented
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Table 3. Standard protocol for PEAS treatment.
Compound Dose
Cholestryramine (CSM, Questran)  One scoop, 9 g, on an empty stomach 30 min before food or taking other 
medication, four times a day for 2 weeks (FDA exemption letter issued 28 June 
1999); CSM should be mixed well in water or apple juice
Sorbitol, 70% solution 15 cc three times a day as needed to relieve constipation
Prilosec (or Prevacid)  Daily, one capsule as needed to treat reﬂux
The dose of CSM used is approved for treatment of hypercholestrolemia by the FDA. 
Figure 1. A simple card test, the Functional Acuity Contrast Test was used to measure VCS in the current
PEAS cases using a standard procedure (6). This test measures contrast sensitivity for ﬁve sizes (spatial fre-
quencies) of light and dark bar patterns (sinusoidal gratings) because spatial vision is mediated by popula-
tions of neurons selectively tuned to different spatial frequency (7). If neurons subserving high
spatial-frequency (smaller bars) vision are functionally impaired but those underlying low spatial-frequency
(larger bars) vision are functionally normal, for example, then visual perception also will be impaired for high
frequency patterns but normal for low frequency patterns. with reappearance of a rash at the same loca-
tion on her breast as in March 1999. Both
patients reported the same set of symptoms
experienced during the ﬁrst episode, although
memory loss and difﬁculty in concentrating
were less severe. (Table 2). Neither had
changes in health or exposure history, and the
laboratory and clinical tests were again nega-
tive. The woman’s VCS was again markedly
reduced (Figure 5), as was her husband’s, and
both were diagnosed with acute PEAS. The
standard regime of CSM treatment produced
excellent results: their symptoms abated and
VCS recovered in less than 2 weeks.
Discussion
Recent evidence has suggested that the estuar-
ine dinoflagellates Pfiesteria piscicida and P.
shumwayae not only kill fish (8–10) on the
Eastern Seaboard from Delaware to Florida
(11) but also may pose a human health risk in
laboratory (12) and natural settings (13–15).
Humans who were exposed to estuaries of the
Chesapeake Bay, Maryland, around the time
of ﬁsh kills in 1997 had severe exposure- and
duration-related reductions in neuropsycho-
logic tests of cognitive and motor functions
relative to unexposed, matched-control study
participants (14). Although the test scores of
affected individuals returned to within
normal ranges in 3–6 months (14), little is
known about the potential acute and chronic
health effects of PEAS (16). The CDC case
deﬁnition of PEAS consists of three compo-
nents: a) exposure potential (symptoms
reported within 2 weeks of exposure to estuar-
ine waters); b) symptoms, including memory
loss or confusion of any duration and/or three
or more selected symptoms (i.e. headache,
skin rash at the site of water contact, sensation
of burning skin, eye irritation, upper respira-
tory irritation, muscle cramps, and gastroin-
testinal symptoms) that, with the exception of
skin rash and burning skin sensation, persist
for > 2 weeks; and c) confounders (a health
care provider cannot identify another cause of
the symptoms). Deﬁnitive diagnosis of PEAS
has been hampered by the lack of identiﬁca-
tion of, and an indicator for, the putative
toxin(s) made by TPC (17) or other readily
available, low-cost objective indicators of
exposure. The ﬁve patients reported here met
the CDC case deﬁnition for PEAS, with the
exception that some cases were successfully
treated during some episodes prior to having
symptoms for 2 weeks (Table 2). Data from
these cases suggested that a measure of visual
function and recognition of additional symp-
toms may assist in the diagnosis of PEAS.
Measurements of VCS, an indicator of the
ability to detect visual patterns, were made
because a study conducted in 1997 showed a
sharp and apparently persistent reduction in
North Carolina watermen exposed to estuar-
ies inhabited by TPC relative to unexposed
offshore watermen (15). In a subsequent
study, VCS was signiﬁcantly lower in water-
men on estuaries where TPC was identiﬁed
than in watermen on estuaries where TPC
sampling was negative (18). The current cases
illustrate the spectrum of symptoms in acute
and chronic PEAS associated with single and
repeated estuarine exposures. Treatment with
the toxin-binding polymer CSM (19) led to
symptom abatement and VCS recovery
within 2 weeks of treatment initiation, appar-
ently by enhancing toxin-elimination rates. 
These cases suggested that PEAS is an
acute illness which develops into chronic ill-
ness in some individuals. All ﬁve cases con-
Grand Rounds in Environmental Medicine • Shoemaker and Hudnell
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Figure 3. Spatial frequency profiles and time-
course of visual contrast sensitivity for Case 3. (A)
VCS remained depressed while the patient was
enrolled in the placebo arm of a double-blinded,
cross-over clinical trial. VCS improved after 2
weeks of CSM treatment. (B) VCS at the midspatial
frequency (VCS-6), where PEAS-related deficits
are typically greatest, is plotted to show the time
course of VCS change. Arrows indicate last day of
exposure before onset of illness. During the first
acute PEAS episode, VCS-6 was depressed 2 days
after exposure and deteriorated further during
placebo treatment. VCS-6 was improved after 4
days of CSM treatment (Rx). Full recovery was
seen after 12 days of treatment and was retained 5
days after treatment cessation. During the second
acute PEAS episode, VCS-6 was markedly
depressed 3 days after exposure (plot day 59) and
showed little change 4 days later when treatment
was initiated. Only slight improvement was seen
after 2 days of treatment, but full recovery was
seen after 8 days of treatment.
Figure 2. Spatial frequency proﬁles of visual contrast sensitivity for Case 2. (A) A normal VCS proﬁle was
measured at the beginning and end of a 2-day project of sampling sediment and water in Maryland estu-
aries known to harbor TPC. (B) Case 2 became symptomatic approximately 24 hr after leaving the estuar-
ies and showed severely depressed VCS, particularly at the midspatial frequency, when seen in the clinic
approximately 62 hr after leaving the estuaries. (C) The patient showed a return of normal VCS after 6 and
9 days of cholestyramine treatment, coincident with symptom abatement. (D) After working in other estu-
aries, the patient experienced a second suspected episode of PEAS and began self-treatment with
cholestyramine. VCS was normal when measured in the clinic after 6 days of treatment and remained
normal 2 days after treatment ended. He returned to the estuaries the next day and was seen in the clinic
3 days later with depressed VCS and a suspect third case of acute PEAS. Cholestyramine was prescribed,
but follow up was not obtained.
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tracted acute PEAS, and Cases 2 and 3
repeatedly acquired acute PEAS. Chronic
PEAS was thought to have been contracted
by Cases 1, 4, and 5. The symptoms, the
VCS deﬁcit, and the response to CSM treat-
ment were similar for acute and chronic
PEAS cases. As shown in Table 2, the most
commonly reported symptoms were cough,
secretory diarrhea, headache, fatigue, mem-
ory impairment, rash, difﬁculty concentrat-
ing, light sensitivity, burning skin upon water
contact, muscle ache, and abdominal pain.
Less frequently encountered symptoms were
upper airway obstruction, shortness of
breath, confusion, red or tearing eyes, weak-
ness, and vertigo. These symptoms suggested
that a variety of organs may be affected in
PEAS, including the brain and nervous sys-
tem (including the visual system), muscle,
mucus membranes, skin, and the gastroin-
testinal system. Effects seen in Cases 1 and 2
suggested that immunologic function may be
compromised, which is consistent with the
report by Glasgow et al. (12). Although these
cases met the CDC symptom criteria for
PEAS, except for the duration requirement as
noted above, expansion of the CDC symp-
tom list might improve case recognition.
These cases illustrate several additional
pertinent points. First, in this limited sample,
PEAS symptoms and the response to treat-
ment did not appear to differ with gender or
age. Second, the onset of acute illness usually
occurred within 24–36 hr after exposure, as
suggested by Cases 2, 3, 4, and 5, and was
indicated by the objective measurement of
VCS. Third, VCS recovery and symptom
abatement began about 48 hr after the initia-
tion of CSM treatment as suggested by Case
2, both acute episodes of Case 3, and the
chronic and acute episodes of Cases 4 and 5.
Fourth, repeat exposure resulted in reacquisi-
tion of illness in all cases. It is unclear whether
repeated acquisition of PEAS was associated
with increased symptom severity because
exposure dose was undefined, or whether
there are cumulative effects. Fifth, individuals
may differ in susceptibility to PEAS. Three
researchers accompanied Case 2 during estu-
arine sampling on 19–20 July 1999 and
received comparable estuarine exposure. Case
2 and one researcher did not take CSM pro-
phylactically. Case 2, but not the non-CSM
researcher, contracted acute PEAS. If PEAS is
caused by TPC toxin(s), the possible biologic
bases for differences in susceptibility are
many; individual responses to TPC toxin(s)
may vary due to differences in absorption or
elimination rates, metabolism, the concentra-
tion of speciﬁc receptor binding sites, endoge-
nous protective ligands, the vulnerability of
target organs to the mechanism(s) of action,
compensatory mechanisms, or other factors.
Sixth, some of these factors also may con-
tribute to individual differences in recovery
rate without treatment. Anecdotal evidence
indicates that some individuals with acute
PEAS do not go on to develop chronic PEAS,
whereas Cases 1, 4, and 5 did so. Of the 10
cases seen at the 3-month follow-up reported
by Grattan et al. (14), two cases had not
returned to the normal range of cognitive
function, Case 1 was in the normal range fol-
lowing CSM treatment, and 7 cases had
returned to the normal range without treat-
ment (14). Seventh, CSM use as a prophylac-
tic may prevent the acquisition of acute PEAS,
as apparently seen in Case 1. The second
researcher who accompanied Case 2 during
sampling used CSM at a standard dose before
exposure and throughout the sampling period,
and did not contract PEAS. The third accom-
panying researcher took only one dose of
CSM before sampling (on a full stomach) and
did contract PEAS. Therefore, prophylactic
use of 2 doses/day CSM may be a reasonable
disease prevention strategy for known suscep-
tible individuals with high potential for expo-
sure to affected estuaries. Eighth, although
conclusive evidence is lacking, PEAS or its
repeated acquisition was temporally associated
with, and may have been a contributing factor
to, the upper airway inﬂammation, pneumo-
nia, and respiratory arrest that resulted in the
death of Case 2. Repeated acute PEAS acqui-
sition may have altered his immunologic
response, predisposing him to pneumonia
development. Furthermore, it is highly
unusual for the clinical course of pneumonia
in a previously healthy 41-year-old male to
include fever and cough reduction in response
to antibiotic treatment, followed paradoxi-
cally by a strong increase in snoring and death
from respiratory arrest. Although eosinophilic
inﬁltration is a nonspeciﬁc response associated
with Addison’s disease, asthma, and parasitic
and other conditions, eosinophilia was previ-
ously observed in skin biopsies from two
patients with acutely acquired, TPC-related
skin lesions (20) and in the study of Grattan
et al. (14). Although speculative, the upper
airway eosinophilic inﬁltration seen in Case 2
at autopsy (21) may have been in response to
TPC toxin(s)-induced inﬂammation, which
led to upper airway obstruction and respira-
tory failure. Appropriate tissue and ﬂuid sam-
ples from Case 2 were preserved for further
analysis when a satisfactory assay for toxin(s)
in human tissue is available.
Previous studies suggested an association
between VCS deﬁcits and hours spent at ﬁsh
kills (15) and work or recreation on TPC-
inhabited estuaries (15,18). The current cases
repeatedly showed severe VCS deﬁcits shortly
after exposure to TPC-inhabited estuaries and
complete VCS recovery following CSM ther-
apy. Case 3 showed no VCS or symptomatic
improvement for 2 weeks while in the
placebo arm of the double-blind, placebo-
controlled, crossover clinical trial on CSM
efﬁcacy. No other neurotoxicant exposures or
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Figure 4. Case 3 acquired acute PEAS a second
time after catching fish with lesions in a
Chesapeake Bay estuary on 16 February 1999
when the water temperature was 42°F. (A) Whole
fish brought to the clinic 3 days later, showing
ulcerative lesions around the anal vent. (B) Close-
up of the anal vent area showing a fresh ulcera-
tive lesion right of the anal vent and a deeper,
older-appearing lesion superior to the anal vent.
Figure 5. Spatial frequency proﬁles of visual contrast sensitivity for Case 5. (A) Case 5 became ill shortly
after catching crabs in an estuary and experienced symptoms of chronic PEAS for approximately 6 months
before seeking medical attention, at which time her VCS was severely depressed. VCS was normal after 2
weeks of CSM treatment. (B) The patient remained well until she returned to the estuary about 4 months
later. At that time, she developed symptoms of acute PEAS, and VCS was again markedly depressed. VCS
again returned to normal after 2 weeks of CSM treatment.
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medications have been reported in the litera-
ture to cause such rapid and dramatic alter-
ations in VCS (6,7). These data suggest that
VCS measurement is useful in both assisting
PEAS diagnosis and monitoring treatment.
Inclusion of the VCS deﬁcit in the CDC case
definition of PEAS would add an objective
component to an otherwise symptomatically
deﬁned syndrome.
VCS is a measure of the ability to detect
visual patterns (6,7,22,23). Whereas stan-
dard tests of visual acuity measure the visual
system’s resolution limit for high contrast
stimuli, a task critically dependent on the
functional integrity of the eye’s physiologic
optics system, VCS is primarily an indicator
of neurologic function in the visual pathways
from the retina to the cortex (7). VCS, but
not visual acuity, improved after CSM treat-
ment in the cases and during the clinical trial,
suggesting a neural rather than optical physio-
logic basis for the impairment. Furthermore,
stronger parvocellular than magnocellular
pathway (24) involvement is suggested by the
effect bias for mid-to-higher spatial frequen-
cies. VCS deficits are not specific for TPC
toxin(s) or PEAS (25). The VCS spatial fre-
quency proﬁle showing greatest reduction at
midspatial frequency in PEAS was similar to
that seen in workers chronically exposed to
organic solvents (6,26). However, VCS
appeared to be an early, persistent, highly
sensitive, inexpensive, and easily measured
indicator of PEAS, which in combination
with information on potential exposure to
estuaries, symptoms, and confounding fac-
tors, greatly assisted in the diagnosis of
PEAS. Both the data from the cases and the
clinical trial (27) suggest that VCS improve-
ment may be strongly associated with symp-
tom subsidence during recovery.
The TPC toxin(s) thought to be respon-
sible for PEAS was not the ﬁrst toxin(s) that
had been effectively eliminated by CSM
treatment. Case reports and animal studies
suggested that CSM binds and enhances
elimination rates of many organic toxins
including Kepone (28,29), DDE (30), other
organochlorine pesticides (31), polychlori-
nated biphenyl compounds (32), Clostridum
difficile toxin (33,34), Escheria coli and
Vibrio cholera toxins (35,36), a cytotoxin(s)
from an unidentified gastrointestinal
microorganism(s) (37,38), the mycotoxins
ochratoxin A (39,40) and fumonisin B1
(41), the cyanobacterial toxin microcystin
LR (42), the fusarium toxin zearalenone
(43), and a toxin from the Chinese herbal
product Jin Bu Huan (44). Toxins that cir-
culate systemically were thought to enter the
small intestine with bile and become bound
by CSM, thereby interrupting enterohepatic
recirculation and preventing systemic recir-
culation. CSM, a highly charged quaternary
ammonium resin, may act as an absorbent
by binding toxins through its strong anion-
exchange capacity or by entrapment of mole-
cules in its polymeric structure. CSM taken
orally is not absorbed due to its large molec-
ular size and is not metabolized in the diges-
tive system. The clinical improvement seen
in the cases treated with CSM was thought
to be due to interruption of enterohepatic
recirculation of toxin(s). Confirmation of
this hypothesis will not be possible until the
toxin, or suite of toxins and their metabo-
lites, are identified. There are intriguing
studies under way (45,46) that focus on the
three-dimensional structure of organic toxins
and the existence of a molecular dipole in
those toxins, particularly in polycyclic ether
toxins identified in other dinoflagellate
species (47) and in carboxylic acid ether tox-
ins of fungal species (40,45,46), into which
the quaternary ammonium side chain of
CSM ﬁts exactly, much as it ﬁts into particu-
lar crown-6-ether structures (48). Further
research is needed to clarify the mechanisms
by which CSM leads to the elimination of
the TPC and other organic toxins.
Although it has been suggested that
treatment of PEAS cases with CSM is pre-
mature (49), we hope that these cases and
the clinical trial will help document the
benefit of CSM use in acute and chronic
PEAS. We suggest that a PEAS diagnosis be
made immediately when: a) VCS at
midspatial frequency (6 cycles/degree) is
< 70 or < 50 at 12 cycles/degree, the
Snellen equivalent visual acuity is at least
20:50, and the CDC symptoms criteria are
met, other than the duration criterion, or
when they are met by including the other
symptoms listed in Table 1; b) the individ-
ual was exposed to estuaries where TPC can
be reasonably suspected around the time of
symptom onset and; c) and no other proba-
ble cause of the symptoms can be found.
There is little reason to withhold treatment
in an acute case because the morbidity of
the illness can cause significant disruption
in quality of life and work performance.
There is also potential for the development
of chronic PEAS or other complications. As
the basic science of molecular biology pro-
ceeds toward identification of toxins (50)
and modes of action (51,52), VCS testing
can assist in accurately diagnosing PEAS,
and the medical standard of care should
include CSM therapy (according to the
standard protocol in Table 3). However,
physicians treating cases with CSM or rec-
ommending its prophylactic use should
know that treatment is not totally benign.
The potential side effects of reflux, bloat-
ing, and constipation can be bothersome
and warrant monitoring and intervention
by the physician as indicated (see Table 3). 
These cases of reexposure and reacquisi-
tion of PEAS suggest that casual exposure to
estuaries inhabited by TPC may be a risk fac-
tor for the acquisition of illness. Although the
acquisition of PEAS was temporally associated
with exposure to estuarine waters inhabited
by TPC, no data directly establish a causal
relationship between exposure to TPC
toxin(s) and development of PEAS. The
definitive establishment of PEAS as a TPC
toxin-mediated illness must await delineation
of the toxin(s) structure and a rigorous test for
its presence in biologic tissue (17). Previous
cases thought to be due to environmental
TPC toxin(s) exposure occurred in warm
weather near the time of large ﬁsh kills (14).
However, there are no conclusive data to sug-
gest that TPC toxin formation in nature
occurs only in the presence of large schools of
ﬁsh or warm water temperatures. The percep-
tion that TPC toxin(s) production occurs
only in warm weather may arise from the fact
that large schools of ﬁsh such an menhaden
are in the estuaries only in warm weather and,
therefore, that is the only time when large ﬁsh
kills can occur. Cases 2, 3, 4, and 5 repeatedly
acquired PEAS in the absence of a large ﬁsh
kill, and Cases 2 and 3 experienced episodes
of acute PEAS following contact with cool
estuarine waters. Research is needed to deter-
mine whether areas of low water ﬂow in shal-
low rivers may provide year-round conditions
for TPC to emerge from the cyst form in
response to unknown signals, perhaps in
widely distributed micro-environments. The
lack of many TPC-related ﬁsh kills in attack
zones of the Eastern Shore of the Chesapeake
Bay in 1999 and 2000 and the continued pre-
sentation of new PEAS cases at the McCready
Outpatient Services Center suggest that sick
patients, in addition to lesioned or dead ﬁsh,
may be indicators of environmental toxin(s).
Research is needed to identify the extent of the
public health risk posed by both single and
repeated episodes of PEAS. VCS measure-
ments and CSM provide safe, inexpensive,
and reliable tools for assisting in the diagnosis
and treatment of PEAS, respectively.
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